Can a Simple Blood Test Predict Breast Cancer Treatment Success?
"New research highlights how the lymphocyte-to-monocyte ratio (LMR) in a standard blood test could help personalize chemotherapy for luminal-type breast cancer."
Breast cancer is a complex disease with different subtypes, each responding uniquely to treatments. Luminal breast cancer, a major subtype, still presents challenges in achieving consistently positive outcomes, driving the search for more refined treatment strategies.
Recent advances in cancer immunology have illuminated the critical role of the body's immune system in cancer development and progression. This has opened doors to immunomodulating therapies and a deeper understanding of how the immune system can influence the response to traditional treatments like chemotherapy.
Now, a new study investigates whether routinely measured components in blood, like the lymphocyte-to-monocyte ratio (LMR), can act as predictive markers in luminal breast cancer. The goal is to identify which patients are most likely to benefit from specific chemotherapy regimens, bringing personalized medicine closer to reality.
The Global Burden of Breast Cancer
Breast cancer remains a major health burden worldwide. The World Health Organization estimated that 2.4 million women were diagnosed with breast cancer and 694,000 died from it in 2024. In the United States, the reported annual rate of new female breast cancer cases was 132.5 per 100,000 women, while the death rate was 18.9 per 100,000 women; the American Cancer Society reports a 91% five-year relative survival rate that declines to 86% at 10 years and 81% at 15 years.
Treatment Depends on Tumor Biology
Traditional breast cancer treatment includes surgery, chemotherapy, radiotherapy, endocrine therapy, and targeted therapy. The neoadjuvant approach and improvements in imaging and understanding of tumor biology have contributed to better survival, but treatment decisions remain complex. Limitations are especially evident in triple-negative breast cancer, for which survival is generally worse than for other subtypes despite significant treatment advances; the NCI also notes that there is no standard approach in some settings.
From Ancient Theories to Targeted Treatment
Breast cancer has been recognized for centuries, although early explanations were medically inaccurate: theories associated with Hippocrates around 460 BCE and Galen around 200 CE attributed disease to an excess of black bile. Later milestones in cancer research and treatment helped establish more effective approaches, including tamoxifen as a treatment for breast cancer. Historical accounts show how the field moved from speculative explanations toward therapies informed by cancer biology.
LMR: A Window into Chemotherapy Response
This study, involving 259 patients with luminal breast cancer, examined the potential of various blood-based markers to predict how well patients would respond to chemotherapy. The research team focused on the lymphocyte-to-monocyte ratio (LMR), a simple calculation derived from a standard blood test.
- LMR Cutoff: A value of 5.2 was identified as the optimal threshold for distinguishing between favorable and less favorable prognoses in luminal breast cancer patients.
- Chemotherapy Regimen: Patients with a high LMR (≥5.2) who received a CEF (cyclophosphamide, epirubicin, 5-fluorouracil) chemotherapy regimen experienced better outcomes than those on a TAC (paclitaxel, doxorubicin, cyclophosphamide) regimen.
- 5-Fluorouracil Sensitivity: Further investigation showed that 5-FU, a component of the CEF regimen, may play a key role, as it was found to enhance the expression of FAS, a protein involved in programmed cell death, in breast cancer cells.
Luminal Subtypes and Prognosis
Recent reviews distinguish luminal A and luminal B breast cancers as biologically different subtypes. Cleveland Clinic describes luminal A as having the best outlook among molecular subtypes, while prognosis still depends on factors such as tumor size and growth rate. Research summarized by BCRF focuses on how experts diagnose and treat luminal B disease and how ongoing research may improve outcomes.
Luminal B Carries Greater Risk
Luminal B breast cancer does not consistently share the favorable outlook associated with luminal A disease. One medical overview reports that luminal B has often been associated with poorer prognosis than luminal A, while a 2025 ESMO Open analysis states that patients with luminal B-like tumors experience a significantly worse prognosis than those with luminal A-like tumors. These findings caution against treating luminal classification as a guarantee of treatment success.
Luminal A Versus Luminal B
Luminal B tumors are generally higher grade and have a worse prognosis than luminal A tumors; they are estrogen-receptor positive, may be progesterone-receptor negative, and often show high Ki-67 expression. BreastCancer.org notes that low Ki-67 levels in luminal A cancers are associated with slower growth, lower grade, and better treatment response. One Cancer Treatment Centers of America comparison reports five-year survival rates of 94.4% for luminal A and 90.7% for luminal B, although those figures come from that source's specific comparison.
Personalizing Breast Cancer Treatment
This research suggests that LMR could be a valuable tool in personalizing treatment decisions for women with luminal breast cancer. By incorporating LMR into the assessment, doctors may be able to better predict which patients will benefit most from specific chemotherapy regimens.
Luminal B Survival in Context
Luminal B breast cancer has a less favorable prognosis than luminal A in many comparisons, but outcomes are not uniformly poor. City of Hope reports an overall five-year relative survival rate of 91.5% for women diagnosed with luminal B breast cancer between 2014 and 2020. That figure provides context for interpreting luminal B as a higher-risk subtype while recognizing that many patients still experience substantial short-term survival.
Toward More Integrated Treatment Research
Future breast cancer research is expected to refine clinical-trial design and integrate multi-omic data. Current treatment options for luminal B breast cancer include hormone therapy, targeted therapy, and surgery, with Cleveland Clinic noting that outlook is more positive when treatment begins earlier. BCRF also reports that luminal B cancers tend to grow faster and have a worse prognosis than luminal A cancers, reinforcing the need for improved risk assessment and treatment strategies.
Early Disease Has Different Stakes
Systemic treatment strategies must account for tumor size, nodal status, hormone-receptor status, and HER2 status rather than relying on one broad breast cancer category. In HR-positive/HER2-negative breast cancer, a recent report states that five-year overall survival and breast-cancer-specific survival exceed 95% for T1a and T1b tumors. These outcomes illustrate how early-stage, small, node-negative disease can have a substantially different risk profile from more advanced disease.
Prognosis Does Not Eliminate Uncertainty
Real-world outcomes can remain uncertain even for breast cancer subtypes generally considered more favorable. A Kaiser Permanente study summary notes that women with luminal A tumors, which are generally thought to have the best prognosis, still faced a risk of death years later. Research on luminal B disease has also described aggressive clinical behavior and a prognosis similar to some non-luminal cancers, underscoring why individual treatment decisions require more than subtype labels alone.
The finding that 5-FU may enhance the expression of FAS, potentially making cancer cells more susceptible to cell death, offers a promising avenue for further research. It suggests that understanding the interplay between chemotherapy drugs and the immune system could lead to more effective treatment strategies.
While these results are encouraging, it's important to remember that this was a single-center study. Further research is needed to validate these findings in larger, more diverse populations and to fully understand the mechanisms by which LMR influences chemotherapy response. However, this study represents a significant step forward in the quest to tailor breast cancer treatment to the individual patient, maximizing the chances of success.